Comprehensive ReviewTreatment of Multiple Myeloma: A Comprehensive Review
References (84)
- et al.
Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment
Mayo Clin Proc
(2006) - et al.
Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement
Mayo Clin Proc
(2007) - et al.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic multiple myeloma
Blood
(2008) - et al.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Blood
(2006) - et al.
Velcade/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial
Blood
(2007) - et al.
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
Blood
(1998) - et al.
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
Blood
(2002) - et al.
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Blood
(2006) - et al.
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Blood
(2008) - et al.
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Blood
(2008)
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome
Blood
(1996)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
Blood
(2005)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Lancet
(2006)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Lancet
(2007)
Clinical course of patients with relapsed multiple myeloma
Mayo Clin Proc
(2004)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Blood
(2001)
S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide
Clin Ther
(1999)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Blood
(2007)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Blood
(2002)
Multiple myeloma
Blood
(2008)
Improved survival in multiple myeloma and the impact of novel therapies
Blood
(2008)
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
Blood
(2005)
Incidence of multiple myeloma in Olmsted County, Minnesota -Trend over 6 decades
Cancer
(2004)
Cancer incidence and mortality, 1973-1995: a report card for the U.S.
Cancer
(1998)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Br J Haematol
(2003)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Leukemia
(2009)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
N Engl J Med
(2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
Leukemia
(2007)
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Br J Haematol
(2001)
Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma
Br J Haematol
(1997)
Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen
Br J Haematol
(2003)
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high dose therapy for multiple myeloma including the role of plerixafor [AMD 3100]
Leukemia
(2009)
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A08): A trial coordinated by the Eastern Cooperative Oncology Group
J Clin Oncol
(2007)
Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (ERA03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome
J Clin Oncol
(2008)
Antitumor activity of thalidomide in refractory multiple myeloma [erratum appears in N Engl J Med 2000; 342:364]
N Engl J Med
(1999)
Multicenter, randomized, doubleblind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
J Clin Oncol
(2008)
Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma
Blood
(2006)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
N Engl J Med
(2008)
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics
J Clin Oncol
(2007)
Bortezomib (Velcade(R))-Thalidomide-Dexamethasone (VTD) vs. Thalidomide-Dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)
Blood
(2007)
Effective treatment of advanced multiple myeloma refractory to alkylating agents
N Engl J Med
(1984)
Cited by (140)
Co-immunizing with PD-L1 induces CD8<sup>+</sup> DCs-mediated anti-tumor immunity in multiple myeloma
2020, International ImmunopharmacologyCitation Excerpt :Multiple myeloma is one of the most common types of hematopoietic malignancies, accounts for 1% of all types of malignancy and more than 10% of the hematologic malignancies [1–3].
scRNA-Seq and Bulk-Seq Analysis Identifies S100A9 Plasma Cells as a Potentially Effective Immunotherapeutic Agent for Multiple Myeloma
2024, Journal of Inflammation ResearchMaculopathy in a 52-Year-Old Patient With Diabetes
2024, JAMA Ophthalmology
This summary may include the discussion of investigational and/or unlabeled uses of drugs and/or devices that may not be approved by the FDA.
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.
Copyright © 2009 Elsevier Inc. All rights reserved.